Analyst Ratings For Cello Health PLC (LON:CLL)
Today, FinnCap reiterated its Corporate rating on Cello Health PLC (LON:CLL).
There are 0 Strong Buy Ratings, no Sell Ratings, no Hold Ratings, no Buy Ratings on the stock.
The current consensus rating on Cello Health PLC (LON:CLL) is N/A with a consensus target price of N/A per share, a potential .
Some recent analyst ratings include
- 1/17/2019-Cello Health PLC (LON:CLL) had its Corporate rating reiterated by FinnCap
- 9/20/2017-Cello Health PLC (LON:CLL) had its Buy rating reiterated by N+1 Singer with a GBX 131 price target
About Cello Health PLC (LON:CLL)
Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients. The Cello Signal segment provides market research and direct communications services principally to consumer-facing clients. Cello Health plc was incorporated in 2004 and is headquartered in London, the United Kingdom.
Recent Trading Activity for Cello Health PLC (LON:CLL)
Shares of Cello Health PLC closed the previous trading session at 109.03 up +1.53 1.42% with 0 shares trading hands.